Beacon Therapeutics

Beacon Therapeutics is a clinical-stage biotechnology company focused on gene therapies for blinding ocular diseases. According to its official website, the company describes itself as "a leading clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases." Its stated disease focus includes X-linked retinitis pigmentosa (XLRP), dry age-related macular degeneration (dAMD) / geographic atrophy (GA), and cone rod dystrophy (CRD), with an additional undisclosed asset in the pipeline. The company's core technology platform is AAV gene therapy. As explained on its site, gene therapy works by modifying a patient's cells to add a functional copy of the mutated gene responsible for a disease, allowing the body to produce proteins that treat or prevent genetic conditions. Beacon emphasizes that a single treatment can provide long-lasting benefits, potentially improving quality of life. Beacon Therapeutics is backed by a syndicate of life-science investors. Its website lists support from Advent Life Sciences, Forbion, Life Sciences at Goldman Sachs Alternatives, Oxford Science Enterprises, the Gund Vision Fund, Syncona Limited, and TCGX, among others. The company is led by CEO Lance Baldo, MD, who the site notes brings more than 20 years of biopharmaceutical leadership experience, including work at Genentech on the launch of two new indications and a new formulation for Lucentis. Beacon highlights a proprietary pipeline addressing both orphan and prevalent diseases, full R&D-to-commercial capabilities, and strategic partnerships to secure GMP drug supply. Its lead program, laru-zova, is in clinical trials for X-linked retinitis pigmentosa, and the company states it is "at the forefront of translating years of scientific innovation into real impact for patients." The company is headquartered in Alachua, Florida, United States, and actively recruits talent to support its mission.

Beacon Therapeutics is a clinical-stage biotechnology company dedicated to ocular gene therapy. Public information about its founding is limited in the supplied evidence; Wikidata records it as a company in Alachua, United States, and its official website presents it as an established clinical-stage organization with a proprietary pipeline and a leadership team experienced in ophthalmology and biopharmaceutical commercialization. The company's scientific focus is AAV gene therapy for retinal diseases. Its website explains the therapeutic rationale: gene therapy modifies a patient's cells by adding a functional copy of the mutated gene responsible for a disease, enabling the patient's own body to produce proteins that treat or prevent genetic conditions. Beacon states that a single treatment can provide long-lasting benefits and potentially improve quality of life. Beacon's pipeline targets several blinding retinal diseases. These include X-linked retinitis pigmentosa (XLRP), for which its lead candidate laru-zova is in clinical trials; geographic atrophy (GA), associated with dry age-related macular degeneration (dAMD); an inherited cone rod dystrophy (CRD); and another undisclosed asset. The company describes its pipeline as proprietary and addressing both orphan and prevalent diseases. Financially, Beacon is supported by a syndicate of life-science investors. Its website names Advent Life Sciences, Forbion, Life Sciences at Goldman Sachs Alternatives, Oxford Science Enterprises, the Gund Vision Fund, Syncona Limited, and TCGX, among others. This backing supports its clinical development and manufacturing strategy, including strategic partnerships intended to secure GMP drug supply. Leadership is a central part of Beacon's public profile. CEO Lance Baldo, MD, is described as bringing more than 20 years of biopharmaceutical leadership experience, including the successful launch of two new indications and a new formulation for Lucentis while at Genentech. The company states it is led by a seasoned leadership team with a proven track record in commercializing ophthalmic treatments. In its own words, Beacon is "entering another groundbreaking moment in ocular gene therapy," citing encouraging clinical trial results for laru-zova in X-linked retinitis pigmentosa. The company positions itself at the forefront of translating scientific innovation into patient impact and emphasizes its deep expertise in gene therapy and ophthalmology as it works to deliver meaningful change in inherited retinal diseases. It also actively recruits talent to support its mission to save and restore vision.

• Beacon Therapeutics is recorded as a company in Alachua, United States, in Wikidata.

• Laru-zova enters clinical trials for X-linked retinitis pigmentosa, with encouraging results cited by the company.

• Beacon is supported by investors including Advent Life Sciences, Forbion, Goldman Sachs Alternatives, Oxford Science Enterprises, the Gund Vision Fund, Syncona, and TCGX.

Clinical-stage ocular gene therapy company targeting both rare and prevalent blinding retinal diseases, with a proprietary AAV platform and full R&D-to-commercial capabilities.

• laru-zova

  Lead gene therapy candidate in clinical trials for X-linked retinitis pigmentosa (XLRP).

• AAV gene therapy platform

  Platform for ophthalmic gene therapy using AAV vectors to deliver functional gene copies.

• Geographic atrophy (GA) program

  Gene therapy candidate targeting geographic atrophy associated with dry age-related macular degeneration.

• Cone rod dystrophy (CRD) program

  Inherited retinal disease gene therapy candidate.

1. 1Home - Beacon Therapeuticsbeacontx.com
2. 2About us - Beacon Therapeuticsbeacontx.com
3. 3Beacon Therapeutics (United States) - Wikidatawikidata.org